Triple receptor agonist
Retatrutide
LY3437943
Phase 3 investigationalAn investigational molecule designed to activate GIP, GLP-1, and glucagon receptors. It is being studied in large clinical trials; it is not an FDA-approved medicine.
FULL RESEARCH GRAPHIC
Retatrutide research overview
A dedicated Cybertide overview of triple-receptor signaling, current investigational status, and the 30 mg research vial.
Tap the graphic to open the full-resolution version.
RESEARCH SIGNAL MAP
04 ACTIVE FIELDSEVIDENCE READOUT
Phase 3 investigationalHuman efficacy and safety are being evaluated in an active Phase 3 program. Results from one study cannot establish broad safety or approval.
BOUNDARY CHECK
CONTEXT REQUIREDRetatrutide should not be presented as a finished weight-loss product while pivotal studies and regulatory review remain incomplete.
SUBMITTED LAB DOCUMENTS
Test results
Reports may describe other strengths or blends. Match the labeled amount, composition, and exact lot to your vial. A report for another strength does not verify your vial. Each record identifies whether an exact lot was supplied.
VIAL REFERENCE
3 mL mixing math & dosing context
Every number is labeled by evidence level. The 3 mL reference calculates concentration and U-100 volume; it does not prove solvent compatibility, sterility, stability, or suitability for injection.
30 mg vial
Change the liquid. See the amount.
Calculation only: vial amount ÷ liquid volume × draw volume. It does not determine what dose to use or confirm product compatibility.
3.0 mL BAC-water workflow
- First confirm that bacteriostatic water and a 3.0 mL final volume are compatible with the exact product and vial capacity.
- Clean both vial stoppers with alcohol and allow them to dry.
- Add the 3.0 mL slowly down the inside wall instead of directing pressure onto the powder.
- Gently roll or swirl until dissolved; do not shake.
- Use product-specific refrigeration and discard guidance. If none exists, do not invent a beyond-use date.
Phase 2 trial: 1–12 mg once weekly
The obesity phase 2 trial studied 1, 4, 8, and 12 mg once weekly; higher-dose groups used starting doses of 2 or 4 mg with escalation every four weeks. Retatrutide remains investigational and has no FDA-approved dose.
Primary study — NEJM retatrutide phase 2 trial ↗U-100 means 100 units = 1.0 mL. Any table result above 100 units exceeds one standard 1 mL U-100 syringe.